Zura Bio Limited Overview
Pro stress-test →Zura Bio is a clinical-stage biotechnology company that develops medicines for immune and inflammatory disorders in the United States. The company is dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs, with the goal of improving efficacy, safety, and dosing convenience for patients.
Strategic Profile
Pro stress-test →The lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies: TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. TibuSHIELD is expanding enrollment to 225 participants with topline data expected in Q4 2026, while TibuSURE is enrolling with topline data expected in H1 2027.
Competitive Landscape
Pro stress-test →Zura Bio operates in the autoimmune and inflammatory disease space, competing with larger established players developing IL-17 and BAFF pathway inhibitors. The dual-pathway bispecific approach differentiates the company's lead candidate from single-target monoclonal antibodies currently approved or in development for hidradenitis suppurativa and systemic sclerosis.
Industry Context
Zura Bio Limited operates in Clinical-stage Biotechnology - Immunology and Inflammatory Disorders.
Key facts
Founded: 2022 · Headquarters: Henderson, Nevada, United States · Employees: 30